Trials / Terminated
TerminatedNCT05179239
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
A Randomized，Double-blind，Controlled，Multi-center Phase III Clinical Study Evaluating SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102 | SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102 |
| DRUG | SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102 | SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102 |
| DRUG | Placebo + paclitaxel + cisplatin/carboplatin ± BP102 | Placebo + paclitaxel + cisplatin/carboplatin ± BP102 |
Timeline
- Start date
- 2022-02-26
- Primary completion
- 2024-08-12
- Completion
- 2024-08-12
- First posted
- 2022-01-05
- Last updated
- 2025-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05179239. Inclusion in this directory is not an endorsement.